---
title: "NIKA PHARMACEUTICALS, INC 1Q 2026: Revenue ($13.36K), Net income ($13.36K), EPS $0— 10-Q Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286145969.md"
description: "Nika Pharmaceuticals, Inc. reported a net loss of $13.36K for Q1 2026, with revenue unchanged from the prior year. The company has signed long-term agreements to enhance its product pipeline and is expanding its manufacturing capabilities in Europe. Despite no revenue-generating operations yet, Nika is preparing for production and has been funded by related-party loans. The diluted EPS remains at $0. The company is also pursuing acquisitions to bolster its product offerings."
datetime: "2026-05-12T19:21:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286145969.md)
  - [en](https://longbridge.com/en/news/286145969.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286145969.md)
---

# NIKA PHARMACEUTICALS, INC 1Q 2026: Revenue ($13.36K), Net income ($13.36K), EPS $0— 10-Q Summary

Nika Pharmaceuticals, Inc. reported first-quarter 2026 results in its 10-Q filing showing a net loss for the quarter. Revenue and net loss each totaled ($13.36K) versus ($12.95K) in the prior-year quarter, while diluted earnings per share were $0.

**Financial Highlights**

Metric

Current quarter

Prior year quarter

YoY change

Revenue¹

($13.36K)

($12.95K)

(3.2%)

Net income²

($13.36K)

($12.95K)

(3.2%)

Diluted EPS³

$0

$0

—

_¹ Reported as “Revenue”. ² Reported as “Net Loss”. ³ Reported as “Loss per share, basic and diluted”._

**Business Highlights**

-   Strategic partnerships: The company signed multiple long-term exclusive agreements (TNG, Carotilen, Physiolong, IPF platform) to expand its product pipeline and rights.
-   Manufacturing buildout: Nika Europe is pursuing a GMP vial production line and planning a pharmaceutical factory to produce injections, tablets and other forms.
-   Geographic and asset moves: Expanded presence through Nika Europe, acquired technologies and experienced temporary ownership changes affecting its European production foothold.
-   Product pipeline momentum: Acquisitions include technologies for three generics and one supplement; a production agreement for ITV-1 is expected to generate per-set margins.
-   Funding and operations: The company had no revenue-generating operations yet and has been funded by related-party loans while preparing production capacity and regulatory steps.

Original SEC Filing: NIKA PHARMACEUTICALS, INC \[ NIKA \] - 10-Q - May. 12, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [562050.CN](https://longbridge.com/en/quote/562050.CN.md)
- [516930.CN](https://longbridge.com/en/quote/516930.CN.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [159849.CN](https://longbridge.com/en/quote/159849.CN.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [512010.CN](https://longbridge.com/en/quote/512010.CN.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [BIS.US](https://longbridge.com/en/quote/BIS.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [516500.CN](https://longbridge.com/en/quote/516500.CN.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)

## Related News & Research

- [Eton Pharmaceuticals Q1 product sales rise driven by portfolio expansion](https://longbridge.com/en/news/286461579.md)
- [Roivant posts unexpected Q4 profit due to Moderna lawsuit settlement gain](https://longbridge.com/en/news/287053604.md)
- [Corvus Pharmaceuticals presents Phase 1 soquelitinib data showing durable remissions, favorable safety](https://longbridge.com/en/news/286404245.md)
- [Enanta Pharma's RSV Bet And Immunology Ambitions](https://longbridge.com/en/news/286895623.md)
- [<![CDATA[Pharmaceutical Executive Daily: FDA Approves Baxdrostat]]>](https://longbridge.com/en/news/286807703.md)